Skip to main content

Select Drug Profiles

Conference Highlights AMCP
Can Technologic Innovations and Formulary Considerations Improve Healthcare Outcomes?
Charles Bankhead
Charles Bankhead
Read More
Original Research
Long-Term Outcomes of a Cardiovascular and Diabetes Risk-Reduction Program Initiated by a Self-Insured Employer
Nicole D. White, PharmD, CDE, Thomas L. Lenz, PharmD, FACLM, Maryann Z. Skrabal, PharmD, CDE, Jessica J. Skradski, PharmD, Louis Lipari, PharmD candidate
Nicole D. White, PharmD, CDE; Thomas L. Lenz, PharmD, FACLM; Maryann Z. Skrabal, PharmD, CDE; Jessica J. Skradski, PharmD; Louis Lipari, PharmD candidate
Stakeholder Perspective
Influencing Patient Outcomes Through Enhanced Multidisease-Focused Interventions
Jack E. Fincham, PhD, RPh
by Jack E. Fincham, PhD, RPh
Read More
FDA Approvals
Oncology Drugs Approved by the FDA in Early 2018
Read More
FDA Approvals
A “Gold Standard” for Population Health? Revisiting the FDA’s Relationship with the Hippocratic Oath
Gillian Woollett, MA, DPhil , Bruce S. Pyenson, FSA, MAAA
Read More
Original Research, Sleep, Practice Management
Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States
Kathleen F. Villa, MS, Nancy L. Reaven, MA, Susan E. Funk, MBA, Karen McGaughey, PhD, Jed Black, MD
Kathleen F. Villa, MS; Nancy L. Reaven, MA; Susan E. Funk, MBA; Karen McGaughey, PhD; Jed Black, MD
Stakeholder Perspective
Accurate Diagnosis of Chronic Diseases Can Reduce Costs and Medical Resource Utilization
James T. Kenney, RPh, MBA
by James T. Kenney, RPh, MBA
Read More
Original Research
Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry
Dimitrios A. Pappas, MD, Robert A. Gerber, PharmD, MA, MBA, Heather J. Litman, PhD, David Gruben, PhD, Jamie Geier, PhD, Winnie D. Hua, MS, Connie Chen, PharmD, Youfu Li, MD, MPH, Joel M. Kremer, MD, John S. Andrews, MD, Jeffrey A. Bourret, PharmD
Dimitrios A. Pappas, MD; Robert A. Gerber, PharmD; Heather J. Litman, PhD; David Gruben, PhD; Jamie Geier, PhD; Winnie D. Hua, MS; Connie Chen, PharmD; Youfu Li, MD, MPH; Joel M. Kremer, MD; John S. Andrews, MD; Jeffrey A. Bourret, PharmD
Stakeholder Perspective
Limited Guidelines and Treatment Success in the Current Standard of Care for Patients with Rheumatoid Arthritis Provide an Opportunity to Inform New Treatment Protocols
Gary Branning, MBA
by Gary Branning, MBA
Read More
Perspectives
Is Adequate Nutrition Cost-Effective?
David B. Nash, MD, MBA
David B. Nash, MD, MBA
Read More
Original Research
Comparing Treatment Modalities for End-Stage Renal Disease: A Meta-Analysis
Gilbert L. Queeley, PhD, Ellen S. Campbell, PhD
Gilbert L. Queeley, PhD, and Ellen S. Campbell, PhD
Stakeholder Perspective
Dialysis Procedures and Health-Related Quality of Life: The Challenge of Creating Evidence-Based Healthcare in End-Stage Renal Disease
Michael F. Murphy, MD, PhD
by Michael F. Murphy, MD, PhD
Read More
Practice Management
New Rivals: Integrating Health Benefits to Provide Comprehensive Patient Care
Gary Branning, MBA, Martha Vater
Gary Branning, MBA, and Martha Vater
Read More
Original Research, Practice Management
Effects of Educational Messaging on Urgent and Emergent Care–Seeking Behaviors Among Publicly Insured Populations
Jesse Cambon, MEng, Tristan Cordier, MPH, Elizabeth L. Munnich, PhD, MPP, Andrew Renda, MD, MPH, Bobby Kapur, MD, MPH, Shkelzen Hoxhaj, MD, MPH, MBA, Meredith Williams, MD, MBA
Jesse Cambon, MEng; Tristan Cordier, MS; Elizabeth L. Munnich, PhD, MPP; Andrew Renda, MD; Bobby Kapur, MD, MPH; Shkelzen Hoxhaj, MD, MPH, MBA; Meredith Williams, MD, MBA
Stakeholder Perspective
Opportunities to Improve Urgent and Emergent Care Utilization
Cody Olsen, PharmD, BCPS
by Cody Olsen, PharmD, BCPS
Read More
Page 71 of 244
Results 701 - 710 of 2438